The Federal Trade Commission is challenging hundreds of pharmaceutical patent listings in an effort to smooth the path to ...
The Federal Trade Commission is stepping up its crackdown on so-called "junk patents," which it contends are ploys intended ...
The letters targeted what agency officials called “junk listings" on patents ... “To the contrary, robust patent listings are inherently pro-competitive." An FTC official declined to answer ...
The FTC intensifies efforts against pharmaceutical patent listings, disputing junk patents for diabetes, weight loss, asthma, ...
On Tuesday, the agency sent warning letters to 10 pharmaceutical companies threatening legal action for improperly listed patents, and notified the FDA that it disputes the accuracy or relevance of ...
disputing the accuracy of some 300 patent listings in the Food and Drug Administration’s so-called “Orange Book.” The crackdown, which comes six months after FTC challenged 10 pharma majors in a ...
In a press release announcing the latest tranche of patent listing disputes, the FTC highlighted specifically its disputes of so-called “junk patent listings” for “blockbuster” weight loss medications ...
AstraZeneca, GSK and Teva among manufacturers accused of “improper” submission of patents | More than 300 patents targeted in ...